US Patent

US11141457 — Oral octreotide therapy and contraceptive methods

Method of Use · Assigned to Amryt Endo Inc · Expires 2040-12-28 · 15y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of administering oral octreotide therapy to a female subject to avoid combined oral contraceptives or use a back-up method for contraception.

USPTO Abstract

This invention relates to methods of administering oral octreotide therapy to a female subject relating to avoidance of combined oral contraceptives or use of a back-up method for contraception.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3232 — octreotide-acetate

Patent Metadata

Patent number
US11141457
Jurisdiction
US
Classification
Method of Use
Expires
2040-12-28
Drug substance claim
No
Drug product claim
No
Assignee
Amryt Endo Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.